Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study

Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study

ChAdOx1-S is a viral vector vaccine developed by AstraZeneca. We aimed to assess the effectiveness of 1 and 2 doses of the ChAdOx1-S vaccine in reducing COVID-19-related in-hospital mortality in individuals with schizophrenia. This is a retrospective cohort study using a nationwide hospital database...

Full description

Saved in:
Bibliographic Details
Main Authors: Tiffany Dyu, Char Leung, Ana Cristina Simões-e-Silva
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
COVID-19
SARS-CoV-2
schizophrenia
mortality
vaccine
ChAdOx1-S
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2379865
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items